FOLH1 and neoplasm: In summary, at 6 months, 30/35 patients showed biochemical response to SABR treatment, while five patients were progressing; three had systemic disease on PSMA PET/CT, while the treated tumor did not show PSMA uptake, and two patients developed rising PSA values without a visible correlate on PET/CT imaging.